Table 2 Clinical performance of current screening methods and models for cross-sectional population (CIN2+)

Current methods in testing set

hrHPV DNA (cobas)

92.49 (90.62–94.37)

75.75 (73.26–78.23)

0.84 (0.83–0.86)

50.86 (48.60–53.13)

hrHPV mRNA (Aptima)

93.68 (91.94–95.43)

81.29 (79.11–83.57)

0.87 (0.86–0.89)

48.25 (45.98–50.53)

hrHPV DNA (Onclarity)

91.36 (89.37–93.34)

78.24 (75.78–80.79)

0.85 (0.83–0.86)

49.63 (47.27–51.99)

HPV16/18 DNA (cobas)

75.44 (72.35–78.52)

93.40 (91.86–94.77)

0.84 (0.83–0.86)

33.42 (31.31–35.59)

HPV16/18 E6

66.52 (62.84–69.93)

97.70 (96.70–98.60)

0.82 (0.80–0.84)

28.84 (26.70–31.05)

p16/Ki-67

85.07 (82.33–87.67)

79.41 (76.89–81.67)

0.82 (0.80–0.84)

45.67 (43.40–47.95)

ASC-US+

95.99 (94.52–97.33)

74.38 (71.72–76.78)

0.85 (0.84–0.87)

53.16 (50.89–55.41)

Co-testing

98.40 (97.33–99.20)

62.04 (59.13–64.70)

0.80 (0.79–0.82)

61.62 (59.40–63.80)

Logistic regression

Base model

92.00 (88.00–95.11)

89.08 (85.63–92.24)

0.91 (0.88–0.93)

42.76 (38.67–46.92)

Base model + E6

92.49 (88.73–95.77)

93.17 (90.44–95.90)

0.93 (0.91–0.95)

42.89 (38.53–47.33)

Base model + GT

92.79 (89.42–96.15)

92.16 (89.22–95.10)

0.92 (0.90–0.95)

42.22 (37.91–46.62)

Base model + E6 + GT

90.31 (86.22–94.39)

94.92 (92.19–97.27)

0.93 (0.90–0.95)

42.04 (37.44–46.74)

Support vector machine

Base model

87.11 (82.22–91.56)

92.24 (89.37–94.83)

0.90 (0.87–0.92)

38.92 (34.90–43.05)

Base model + E6

92.96 (89.20–96.24)

88.40 (84.98–91.81)

0.91 (0.88–0.93)

45.85 (41.44–50.30)

Base model + GT

87.02 (82.21–91.35)

91.18 (87.91–94.12)

0.89 (0.86–0.92)

40.47 (36.19–44.85)

Base model + E6 + GT

88.78 (84.18–92.86)

91.80 (88.28–94.92)

0.90 (0.88–0.93)

43.14 (38.52–47.85)